INTRODUCTION
============

Osteoarthritis (OA) is one of the most common causes of chronic pain in adults worldwide \[[@b1-kjim-2018-460]-[@b3-kjim-2018-460]\]. Elderly Korean adults with OA report significantly higher pain scores than their peers, and experience significant declines in functional capacity and quality of life as a result of the disease \[[@b4-kjim-2018-460]\]. The chronic pain experienced by individuals with OA has been partially attributed to a biological process called central sensitization, which may be driven by painful stimuli that originate from damaged bone and joint tissue \[[@b5-kjim-2018-460]\]. Central sensitization has been observed both in animal and human models of OA \[[@b6-kjim-2018-460]-[@b8-kjim-2018-460]\]. In addition to chronic pain and disability, approximately 21% of adults with OA are diagnosed with concomitant depression \[[@b9-kjim-2018-460]\]. Individuals who experience OA with comorbid depression report higher healthcare utilization costs than those without, and they have been shown to use pain medication more frequently \[[@b10-kjim-2018-460]\]. These individuals are also less likely to practice adequate adherence to recommended treatment regimens than patients with OA who have not been diagnosed with depression \[[@b10-kjim-2018-460]\]. Duloxetine is a serotonin and norepinephrine reuptake inhibitor that has demonstrated effective relief of persistent pain in animal models of central sensitization in OA, and randomized clinical trial (RCT) data in OA patients have shown promising results for symptom relief \[[@b8-kjim-2018-460]\]. We conducted a systematic review and meta-analysis to assess the safety and efficacy of Duloxetine in patients with OA.

DATA SOURCES/SEARCHES
=====================

We conducted a systematic search of the MEDLINE, EMBASE, Google Scholar, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to December 2018 ([Appendix 1](#app1-kjim-2018-460){ref-type="app"}). Reference lists of relevant systematic reviews and supplements of conference proceedings published up until December 2018 were reviewed by hand. We limited the search to RCTs in human subjects with OA of any joint location, but did not place any limits on language, publication date, or publication status ([Supplementary Table 1](#SD1-kjim-2018-460){ref-type="supplementary-material"}) \[[@b11-kjim-2018-460]\].

STUDY SELECTION
===============

RCTs that assessed the efficacy of duloxetine versus a matching placebo in participants with a clinical diagnosis of OA were considered eligible. Among these, we included studies that reported data from validated scales assessing pain, functional status, depression, and quality of life, as well as data on adverse events. Abstract and full-text screening was performed by two independent reviewers, according to the established inclusion criteria.

DATA EXTRACTION AND QUALITY ASSESSMENT
======================================

Data from the included RCTs were extracted into RevMan software by two independent reviewers \[[@b12-kjim-2018-460]\]. Information was collected on study characteristics and demographic characteristics of the sample, duloxetine dosing regimen, concomitant medication usage, and rescue medication protocols. Quality assessments were performed independently by two reviewers within RevMan using the Cochrane Risk of Bias tool \[[@b13-kjim-2018-460]\].

Outcome definitions
-------------------

The primary outcomes of pain and function assessed by validated scales were collected as mean change from baseline to study follow-up. Secondary outcomes of depression and quality of life assessed by validated scales were also collected as mean change from baseline to study follow-up; a standard directionality of these scales was established *a priori* so that improvement was reflected in decreases in depression scores and increases in quality of life scores. Discontinuations due to adverse events included any participants who discontinued study medication or ceased participation in the study because of an adverse event, regardless of its association to the study medication. Withdrawals due to adverse events were collected only within the RCT follow-up time. Treatment-emergent adverse events (TEAEs) included any adverse event that originated after the initiation of the study medication; these events may or may not be related to the study medication. Serious adverse events (SAEs) were strictly defined as events that were specifically classified by study personnel as "Serious Adverse Events" within the timeframe of the study. Data on the incidence of gastrointestinal (GI) adverse events was collected because GI symptoms are known side effects of duloxetine \[[@b14-kjim-2018-460],[@b15-kjim-2018-460]\].

Statistical analysis
--------------------

We calculated standardized mean differences (SMDs) and 95% confidence intervals (CI) using the DerSimonian and Laird \[[@b16-kjim-2018-460]\] inverse variance method. In the anticipation of clinical and methodological heterogeneity, we conducted meta-analyses using random effects models \[[@b16-kjim-2018-460]\]. Dichotomous outcomes were analyzed using the Mantel-Haenszel method, and we reported the results as risk ratios (RRs) with 95% CIs \[[@b17-kjim-2018-460]\]. We measured inconsistency by the *I*^2^ statistic, and between-trial variance was assessed using Tau squared. Meta-analyses were conducted using RevMan software \[[@b18-kjim-2018-460],[@b19-kjim-2018-460]\].

Sensitivity analyses were conducted by excluding "very low quality" RCTs. "Very low quality" refers to those RCTs that received ≥ 2 high risk of bias ratings; or one specific high risk rating in the "other" category in addition to ≥ 2 unclear risk ratings; or ≥ 3 unclear risk of bias ratings in dimensions other than the "other" category using the Cochrane risk of bias tool RCTs assessing the individual efficacy of various doses/dosing regimens of duloxetine indicate no differences between doses or dosing schedules; therefore, we did not plan separate subgroup analyses to account for these factors \[[@b20-kjim-2018-460]\].

RESULTS
=======

Our systematic search returned 63 references ([Fig. 1](#f1-kjim-2018-460){ref-type="fig"}). Of these, seven RCTs (n = 2,102 participants) comparing duloxetine to a matching placebo met our inclusion criteria \[[@b21-kjim-2018-460]-[@b27-kjim-2018-460]\]. Included RCTs were published between 2009 and 2018. The mean age of participants ranged from 60.5 to 68.7 years (median, 62.3), and the proportion of female participants ranged from 57.1% to 83.7% (median, 76.7%). All studies administered duloxetine at 60 mg/day. Seven studies described titration and tapering periods for duloxetine dosing in detail, with three studies allowing for dose modification from 60 to 120 mg/day ([Table 1](#t1-kjim-2018-460){ref-type="table"}). The majority of studies allowed for limited use of analgesics as rescue medication during the study period. In two studies, continuation of the current regimen of acetaminophen or nonsteroidal anti-inflammatory drug (NSAID) was permitted, and in one study, continuation and optimization of a current NSAID was a part of the study protocol.

Study quality of most RCTs was assessed to be moderate to high; one study received a very low quality rating due to insufficient detail in methodological reporting ([Figs. 2](#f2-kjim-2018-460){ref-type="fig"} and [3](#f3-kjim-2018-460){ref-type="fig"}) \[[@b24-kjim-2018-460]\]. High discontinuation rates were observed in over half of the RCTs, and differential discontinuation rates and/or reasons were observed in the duloxetine groups versus placebo groups in three of these cases \[[@b23-kjim-2018-460],[@b24-kjim-2018-460],[@b27-kjim-2018-460]\]. Two RCTs were excluded from the final analyses: the research team associated with one RCT had been previously flagged for research misconduct, prompting removal of the study from the analysis; the other RCT was the only study involving participants with hand OA; thus, there was insufficient RCT data to merit meta-analysis \[[@b21-kjim-2018-460],[@b27-kjim-2018-460],[@b28-kjim-2018-460]\].

All five of the studies that were eligible for meta-analysis were conducted in participants with knee OA \[[@b22-kjim-2018-460]-[@b26-kjim-2018-460]\]. The follow-up time for all studies ranged from 12 to 14 weeks.

Efficacy and safety of duloxetine in knee OA
--------------------------------------------

### Pain and function

The results of efficacy and safety analyses are displayed in [Table 2](#t2-kjim-2018-460){ref-type="table"}. Pain was reported in all five RCTs that were eligible for analysis (n = 1,713 participants) \[[@b22-kjim-2018-460]-[@b26-kjim-2018-460]\]. Duloxetine demonstrated moderate and statistically significant effects on pain reduction over a 12- to 14-week follow-up (SMD, --0.38; 95% CI, --0.48 to --0.28). Sensitivity analysis excluding one very low quality study produced similar results, with an effect size of --0.39 (95% CI, --0.52 to --0.25). Functional improvement was reported in all five RCTs (n = 1,695 participants), and duloxetine demonstrated modest, statistically significant benefits (SMD, --0.35; 95% CI, --0.46 to --0.24) within 12 to 14 weeks. The results of sensitivity analysis excluding one very low quality study were no different from the main results (SMD, --0.33; 95% CI, --0.47 to --0.18). Assessments of *I*^2^ and *T*^2^ revealed minimal heterogeneity between studies, for all analyses.

### Depression and quality of life

Based on the data from two RCTs (n = 584), duloxetine did not show any significant benefits on depression symptoms \[[@b22-kjim-2018-460],[@b25-kjim-2018-460]\]. Three RCTs reported data on quality of life (n = 826) \[[@b22-kjim-2018-460],[@b23-kjim-2018-460],[@b25-kjim-2018-460]\]. Participants receiving duloxetine reported statistically significant benefits on quality of life outcomes versus the placebo groups (SMD, 0.40; 95% CI, 0.26 to 0.53), with minimal heterogeneity observed between studies.

### Discontinuations due to adverse events

All five included RCTs reported discontinuation due to adverse event (DAE, n = 1,772). Individuals receiving duloxetine were twice as likely to discontinue during the study period due to an adverse event (RR, 2.17; 95% CI, 1.57 to 3.01). Heterogeneity between the study estimates was assessed to be negligible.

### TEAEs and SAEs

Five studies reported TEAEs and SAEs (n = 1,762). TEAEs were about 50% more likely to occur in participants receiving duloxetine (RR, 1.53; 95% CI, 1.21 to 1.92). The rates of SAEs were equal between the two groups, with no statistically significant differences observed.

### Gastrointestinal adverse events

Among the five RCTs (n = 1,762) that reported on gastrointestinal adverse events (GIAEs), participants receiving duloxetine were nearly 4.5 times more likely to experience an event (RR, 4.43; 95% CI, 3.45 to 5.69). Heterogeneity between the studies was negligible. The most commonly reported GIAE were nausea, constipation, and dry mouth.

Efficacy of duloxetine in hand OA
---------------------------------

The RCT (n = 43) assessing the efficacy of duloxetine in hand OA patients reported no statistically significant differences between the duloxetine and placebo groups with regard to pain, function, or depression outcomes \[[@b27-kjim-2018-460]\]. The proportion of participants experiencing GIAE was over three times higher in the duloxetine group than in the placebo group in this study. Given the small sample size, no definitive conclusions can be drawn for all hand OA patients from these results.

DISCUSSION
==========

The results of our study indicate that duloxetine has statistically significant, moderate benefits on pain and function in knee OA patients for up to 3 months. The effect sizes observed for pain and functional improvement were comparable to those reported for prescription doses of NSAIDs for knee OA \[[@b29-kjim-2018-460]\]. Despite the potential benefits of duloxetine, reported incidences of GIAE were three to four times higher in participants with both knee and hand OA who received the intervention versus placebo.

Our results are consistent with previous meta-analyses of duloxetine in knee OA, despite the addition of two new RCTs \[[@b30-kjim-2018-460],[@b31-kjim-2018-460]\]. Previous meta-analyses have reported statistically significant benefits of the drug on pain and function, with statistically significantly higher incidences of TEAEs and DAEs.

Interestingly, the results of our study on depression are also consistent with the most recent meta-analyses that compared duloxetine with other antidepressants \[[@b32-kjim-2018-460],[@b33-kjim-2018-460]\]. The authors of a 2012 Cochrane review concluded that duloxetine was not an appropriate first line treatment for major depressive disorder due to its unfavorable adverse event profile and high cost. Duloxetine was not highly ranked with regard to efficacy in mitigating depressive symptoms in either review, and both reviews highlighted its high potential for adverse GI side effects. Our study showed that while duloxetine demonstrated moderate and significant benefits on knee OA symptoms over the course of 13 weeks, the observed effect sizes were not superior to those that are observed in meta-analyses of conventional treatments such as NSAIDs. Additionally, the adverse event profile was similar to that of NSAIDs, particularly with regard to disproportionately more DAE in the intervention group and the incidence of GIAE. It is important to note; however, that the most commonly reported GIAEs among duloxetine users were minor and transient and included nausea, constipation, and decreased appetite. Longer term safety data are required to determine whether duloxetine could be a viable alternative to NSAIDs with regard to the reduction of risk for serious GIAEs such as intestinal bleeding and ulceration \[[@b34-kjim-2018-460]\].

Duloxetine demonstrated significant beneficial effects on quality of life in knee OA patients. A recent cost-utility analysis highlighted the specific benefits of duloxetine on quality of life and as such, ranked it more favorably than NSAIDs and opioid medications; these results were particularly applicable to patients who are more susceptible to NSAID-specific adverse events \[[@b35-kjim-2018-460]\]. Despite the specific intention of duloxetine to act on depressive symptoms, use of the drug did not result in statistically significant improvement of symptoms of depression in any of the included RCTs in OA patients. The reason for this may be that in most of the included RCTs, individuals with psychiatric disorders or major depressive disorders were excluded.

Quality assessment and the results of our meta-analysis of DAE suggest a potential for bias due to differential rates of DAE. A methodological analysis of duloxetine trials in chronic pain populations highlighted differential DAE rates in participants receiving the drug and concluded that imputation methods using the last observation carried forward (LOCF) method could inflate the observed treatment effect of duloxetine in clinical trials \[[@b20-kjim-2018-460]\]. We acknowledge that such bias may have impacted the results of our study, with the overall effect sizes for pain and function being potentially biased in favor of duloxetine.

CONCLUSIONS
===========

The results of our study indicate that duloxetine may be an effective treatment option for individuals with OA, but that use of the drug is associated with a significantly higher risk of adverse events. Patient preferences, cost considerations, and clinicians' judgment must be taken into account before the initiation of a duloxetine regimen. Future RCTs should be conducted in patients who have concomitant OA and depression to assess the specific benefits of duloxetine in these populations, and to address the real-world scenario in which duloxetine may be a more favorable option. Studies focused on the safety of long-term use of the drug should also be conducted, to assess its eligibility as an alternative to conventional treatments that are associated with a risk of SAEs with long-term use.

No potential conflict of interest relevant to this article was reported.

Supplementary Material
======================

###### Supplementary Table 1.

PRISMA 2009 checklist

1\. duloxetine.mp. \[mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms\]

2\. exp osteoarthritis/ or osteoarthriti\$.ti,ab. or osteoarthro\$.ti,ab. or gonarthriti\$.ti,ab. or gonarthro\$.ti,ab. or coxarthriti\$.ti,ab. or coxarthro\$.ti,ab. or arthros\$.ti,ab. or arthrot\$.ti,ab.

3\. exp randomized controlled trials/

4\. exp random allocation/

5\. exp double-blind method/

6\. exp single blind method/

7\. exp cross-over studies/

8\. exp clinical trial/

9\. randomized controlled trial.pt.

10\. controlled clinical trial.pt.

11\. (random\$ or rct).tw.

12\. (clin\$ adj25 trial\$).tw.

13\. ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).tw.

14\. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13

15\. 1 and 2 and 14

16\. limit 15 to humans

17\. remove duplicates from 16

![Study flow diagram. OA, osteoarthritis; RCT, randomized clinical trial.](kjim-2018-460f1){#f1-kjim-2018-460}

![Risk of bias summary](kjim-2018-460f2){#f2-kjim-2018-460}

![Risk of bias distribution.](kjim-2018-460f3){#f3-kjim-2018-460}

###### 

Characteristics of studies gathered by the systematic search

  Study                                OA joint location                                     Total no.   Mean age, yr   Female sex, %   Comparison                                             Rescue analgesia/Concomitant medication                                                                                        Dose titration, taper               Study duration, wk   Outcomes extracted
  ------------------------------------ ----------------------------------------------------- ----------- -------------- --------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------- -------------------- ------------------------------------------------------------------------------
  Abou-Raya et al. (2012) \[21\]       Knee                                                  288         69             83.7            Duloxetine 60 mg QD vs. Placebo                        Acetaminophen up to 4 g/day and NSAIDs allowed, provided no dose increase                                                      ND                                  16                   None: study excluded due to reported misconduct of responsible research team
  Chappell et al. (2009) \[22\]        Knee                                                  231         62             34.6            Duloxetine 60--120 mg QD vs. Placebo                   Continuation of acetaminophen or NSAID permitted; Use of short-acting analgesics allowed for no more than 3 consecutive days   60 mg: 2 wk titration, 2 wk taper   13                   WOMAC Pain, WOMAC Function, EQ-5D, BDI, DAE, TEAE, SAE, GIAE
  120 mg: 7 wk titration, 2 wk taper                                                                                                                                                                                                                                                                                                                                                   
  Chappell et al. (2011) \[23\]        Knee                                                  256         63             77.0            Duloxetine 60--120 mg QD vs. Placebo                   Continuation of acetaminophen or NSAID permitted; Use of short-acting analgesics allowed for ≤ 3 consecutive days              60 mg: 2 wk titration, 2 wk taper   13                   BPI average pain, WOMAC Function, SF-36, DAE, TEAE, SAE, GIAE
  120 mg: 7 wk titration, 2 wk taper                                                                                                                                                                                                                                                                                                                                                   
  Frakes et al. (2011) \[24\]          Knee                                                  524         61             57.1            Duloxetine 60--120 mg QD + NSAID vs. Placebo + NSAID   Continuation & optimization of current NSAID; Acetaminophen rescue medication ≤ 2.6 g/day for ≤ 25 total days                  60 mg: 1 wk titration, 2 wk taper   12                   WOMAC Pain, WOMAC Function, DAE, TEAE, SAE, GIAE
  120 mg: 3 wk titration, 2 wk taper                                                                                                                                                                                                                                                                                                                                                   
  Uchio et al. (2018) \[25\]           Knee                                                  353         66             77.6            Duloxetine 60 mg QD vs. Placebo                        Use of analgesics permitted as rescue medication for ≤ 3 consecutive days and ≤ 20 total days                                  60 mg: 2 wk titration, 1 wk taper   14                   WOMAC Pain, WOMAC Function, EQ-5D, SF-36 Mental Health, DAE, TEAE, SAE, GIAE
  Wang et al. (2017) \[26\]            Knee^[a](#tfn1-kjim-2018-460){ref-type="table-fn"}^   407         61             76.4            Duloxetine 60 mg QD vs. Placebo                        Use of analgesics permitted as rescue medication for ≤ 3 consecutive days and ≤ 20 total days                                  60 mg: 1 wk titration, 1 wk taper   13                   WOMAC Pain, WOMAC Function, DAE, TEAE, SAE, GIAE
  Sofat et al. (2017) \[27\]           Hand                                                  43          62             76.7            Duloxetine 60 mg QD vs. Placebo                        Acetaminophen rescue medication (dose unclear)                                                                                 60 mg: 2 wk titration, 2 wk taper   13                   None: insufficient data in hand OA to merit metaanalysis

OA, osteoarthritis; QD, per day; NSAID, nonsteroidal anti-inflammatory drug; ND, no data; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; EQ-5D, EuroQol-5D; BDI, Beck Depression Inventory; DAE, discontinuation due to adverse event; TEAE, treatment-emergent adverse event; SAE, serious adverse event; GIAE, gastrointestinal adverse event; SF-36, Medical Outcomes Study Short Form 36-Item Survey.

Inclusion criteria allowed for knee or hip OA, but 99.3% of the participants had knee OA.

###### 

Meta-analysis results

  Outcome                                                No. of RCTs   No. of patients   Effect estimate (95% CI)
  ------------------------------------------------------ ------------- ----------------- -----------------------------------------------------------------------------------------
  Pain \[22-26\]                                         5             1,713             SMD --0.38 (--0.48 to --0.28); *I*^2^ = 5%, *T*^2^ = 0
  Function \[22-26\]                                     5             1,695             SMD --0.35 (--0.46 to --0.24); *I*^2^ = 23%, *T*^2^ = 0
  Depression \[22,25\]                                   2             584               SMD --0.09 (--0.26 to 0.07); *I*^2^ = 0%, *T*^2^ = 0
  Quality of life \[22,23,25\]                           3             826               SMD 0.40 (0.26 to 0.53); *I*^2^ = 0%, *T*^2^ = 0
  Discontinuation due to adverse event(s), % \[22-26\]   5             1,772             RR 2.17 (1.57 to 3.01); *I*^2^ = 0%, *T*^2^ = 0 (duloxetine: 12.4%; placebo: 5.5%)
  Treatment-emergent adverse event(s), % \[22-26\]       5             1,762             RR 1.53 (1.21 to 1.92); *I*^2^ = 77%, *T*^2^ = 0.05 (duloxetine: 55.1%; placebo: 37.4%)
  Serious adverse event(s), % \[22-26\]                  5             1,762             RR 1.03 (0.42 to 2.54); *I*^2^ = 0% *T*^2^ = 0 (duloxetine: 1.1%; placebo: 1.2%)
  Gastrointestinal adverse event(s), % \[22-26\]         5             1,762             RR 4.43 (3.45 to 5.69); *I*^2^ = 4%, *T*^2^ = 0 (duloxetine: 35.5%; placebo: 7.7%)
